NuVasive

NuVasive, Inc. engages in the development, manufacture, sale, and provision of procedural solutions for spine surgery. It offers a comprehensive portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NuVasive is a medical device company that creates minimally invasive surgical products and procedurally integrated spine solutions. Its minimally invasive, procedurally integrated surgical solutions are intended to produce repeatable and clinically proven results.

According to NuVasive (NUVA), the combined company is set to have an advanced commercial scale and portfolio of clinically proven solutions.

NuVasive (NUVA), GMED Merger Aids, Macro Woes Mar Growth

SAN DIEGO , March 14, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced its continued participation at the 2023 Spine Summit held March 16-19 in Miami and the International Meeting on Advanced Spine Techniques (IMAST) held March 22-25 in Dublin. "The Scoliosis Research Society (SRS), American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) are leading societies that help gather our industry through a shared vision of ongoing research, scientific and educational efforts for better patient care," said Chris Barry, chief executive officer at NuVasive.

NuVasive to Participate in Upcoming Spine Society Annual Conferences

NuVasive commemorates industry-defining innovation in the lateral procedural segment SAN DIEGO , March 13, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the 20-year milestone achievement of its lateral lumbar procedure, extreme lateral interbody fusion (XLIF). "20 years ago, we set out to make spine surgery more reproducible and improve patient outcomes through the development and introduction of the XLIF procedure," said Ryan Donahoe, chief technology officer at NuVasive.

NuVasive Celebrates 20-Year Milestone of the XLIF Procedure

Softer results for spinal surgery innovator plus questionable merger have dropped estimates and shares

Bear of the Day: NuVasive (NUVA)

SAN DIEGO , Feb. 27, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that NuVasive management will participate in upcoming investor conferences and will be joined by Globus Medical management to discuss the two companies' recent merger announcement and other business topics: Citi 2023 Healthcare Services, MedTech, Tools and HCIT Conference, March 2, 2023 in New York City. The fireside chat will begin at 9:30 a.m.

NuVasive to Participate in Upcoming Investor Conferences

Inflationary costs, supply chain disruptions, volatility in foreign exchange rates and the persistent COVID-led impact hurt NuVasive's (NUVA) Q4 revenues.

NuVasive (NUVA) Q4 Earnings Miss Estimates, Margins Down

NuVasive, Inc. (NASDAQ:NUVA ) Q4 2022 Earnings Conference Call February 22, 2023 4:30 PM ET Company Participants Juliet Cunningham - VP, IR Christopher Barry - CEO & Director Matthew Harbaugh - EVP & CFO Conference Call Participants Matthew Miksic - Barclays Bank Shagun Chadha - RBC Capital Markets Eric Anderson - Cowen and Company Joseph Conway - Needham & Company Andrew Ranieri - Morgan Stanley Lilia-Celine Lozada - JPMorgan Chase & Co. Vikramjeet Chopra - Wells Fargo Securities Operator Good day, ladies and gentlemen, and welcome to the NuVasive Fourth Quarter and Full Year 2022 Earnings Conference Call. I would now like to introduce your host for today's call, Ms.

NuVasive, Inc. (NUVA) Q4 2022 Earnings Call Transcript

NuVasive (NUVA) delivered earnings and revenue surprises of -12.24% and 1.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

NuVasive (NUVA) Q4 Earnings and Revenues Miss Estimates

– Full-year 2022 net sales grew 5.5% as reported, 8.5% on a constant currency basis – – Continued strong international growth in 2022 – – U.S. cervical delivers growth of greater than 20% year-over-year driven by C360 – – 2,000+ Pulse cases performed worldwide since commercial launch – SAN DIEGO , Feb. 22, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter and full year ended December 31, 2022. Fourth Quarter 2022 Net sales were $305.4 million, a 1.1% increase as reported and a 4.8% increase on a constant currency basis, compared to the prior year period; Net sales were negatively impacted by approximately $11 million due to fluctuations in foreign currency exchange rates compared to the prior year period; GAAP operating margin of 7.1%; Non-GAAP operating margin of 11.3%; and GAAP diluted earnings per share of $0.42; Non-GAAP diluted earnings per share of $0.43.

NuVasive Announces Fourth Quarter and Full-Year 2022 Financial Results and 2023 Net Sales Guidance

Attrax Putty is now on-label for use with cervical Modulus interbody implants SAN DIEGO , Feb. 21, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the use of its Modulus Cervical interbody implant with a bone void filler, further enhancing the Company's C360 portfolio. The expanded indications deliver new value in the cervical segment to surgeons and hospitals.

NuVasive Enhances C360 Portfolio with Expanded Indications for Modulus Cervical and Attrax Putty

NEW YORK , Feb. 13, 2023 /PRNewswire/ --  Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating NuVasive, Inc. (NASDAQ: NUVA), relating to its proposed sale to Globus Medical, Inc. Under the terms of the agreement, NUVA shareholders are expected to receive 0.75 shares of Globus per share they own. Click here for more information: https://www.monteverdelaw.com/case/nuvasive-inc.

ALERT: The M&A Class Action Firm Announces the Investigation of NuVasive, Inc. - NUVA

Globus Medical

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of NuVasive, Inc. (NasdaqGS: NUVA) to Globus Medical, Inc. (NYSE: GMED). Under the terms of the proposed transaction, shareholders of NuVasive will receive 0.75 of a share of Globus Medical Class A common stock for each share of NuVasive that they own.

NUVASIVE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NuVasive, Inc. - NUVA

Globus and NuVasive agreed to merge in a deal that will see Globus acquire its spinal surgery rival for 0.75 shares of GMED per NUVA share (or $3.1B). Globus shares sold off sharply, as the Street clearly isn't sold on the advantages of the deal and/or Globus management's ability to fix NUVA's longstanding margin issues.

Globus And NuVasive Take Spinal Fusion To A New Level

NEW YORK , Feb. 9, 2023 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by NuVasive, Inc. (NASDAQ: NUVA) and its board of directors concerning the proposed acquisition of the company by Globus Medical, Inc. (NYSE: GMED). Stockholders will receive 0.75 shares of Globus Medical Class A common stock for each share of NuVasive, Inc. stock that they hold.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of NuVasive, Inc.

Wilmington, Delaware--(Newsfile Corp. - February 9, 2023) - Rigrodsky Law, P.A. is investigating NuVasive, Inc. ("NuVasive") (NASDAQ: NUVA) regarding possible breaches of fiduciary duties and other violations of law related to NuVasive's agreement to be acquired by Globus Medical, Inc. ("Globus"). Under the terms of the agreement, each NuVasive share will be exchanged for 0.75 shares of Globus.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-nuvasive-inc.To contact Seth D.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating NuVasive, Inc. Buyout

MILWAUKEE , Feb. 9, 2023 /PRNewswire/ -- Ademi LLP is investigating NuVasive (NASDAQ: NUVA) for possible breaches of fiduciary duty and other violations of law in its transaction with Globus Medical.  Click here to learn how to join the action https://www.ademilaw.com/case/nuvasive-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether NuVasive, Inc. has obtained a Fair Price in its transaction with Globus Medical

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of NuVasive, Inc. (NASDAQ: NUVA) to Globus Medical, Inc. for 0.75 of a share of Globus Medical Class A common stock for each share of NuVasive common stock is fair to NuVasive shareholders. Halper Sadeh encourages NuVasive shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.

NUVA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NuVasive, Inc. Is Fair to Shareholders

The implied price for NuVasive under terms of the deal is $57.72 a share.

Globus Medical to Buy NuVasive in $3.1 Billion Deal

Globus Medical GMED, -1.18% said Thursday it will pay 0.75 a share of its stock for each share of NuVasive NUVA, -2.41% stock in a deal that values NuVasive at about $3.1 billion or $57.72 a share. Globus Medical stock is down 12% in premarket trades, while NuVasive stock is rallying 11.9%.

NuVasive rallies while Globus Medical moves down after companies announce all-stock merger deal

Capitalizes on complementary global commercial organizations and accelerates Globus Medical's and NuVasive's globalization strategies to increase customer reach and deepen surgeon relationships Brings together innovative technologies to create comprehensive procedural solutions offering to better support surgeons, healthcare providers and patients Leverages shared commitment to innovation to further both companies' efforts to address the full continuum of care and help solve unmet clinical needs Expands operational excellence capabilities to further serve and enable the combined commercial organizations to better support customers Strong financial profile and value creation opportunity Companies to host joint conference call today at 8 a.m. ET AUDUBON, Pa.

Globus Medical and NuVasive to Combine in All-Stock Transaction to Create Innovative Global Musculoskeletal Company Focused on Patient Care

SAN DIEGO , Jan. 30, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its fourth quarter and full-year 2022 results on Wednesday, February 22, 2023, after the close of the market. NuVasive will hold a conference call on Wednesday, February 22, 2023, at 1:30 p.m.

NuVasive Announces Conference Call and Webcast of Fourth Quarter and Full-Year 2022 Results

NuVasive (NUVA) believes that its 2022 guidance is appropriately conservative, considering macroeconomic pressures on net sales and operating profit.

NuVasive (NUVA) Suffers From Macro Headwinds, Price Issue

NuVasive is a strong medical technology play driven by its revenue growth opportunities in the area of less invasive spine surgery. The company's modern less invasive spine surgery techniques can boost its revenue growth to a significant extent in the long term.

NuVasive: An Excellent Growth Story In Spine Surgery

SAN DIEGO , Dec. 12, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that Chief Executive Officer Chris Barry will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 12, 2023 at 7:30 a.m.

NuVasive to Participate in the 41st Annual J.P. Morgan Healthcare Conference

The continued demand for NuVasive's (NUVA) Simplified Cervical Disc is encouraging.

News for NuVasive Stock (NUVA)